Extracorporeal Membrane Oxygenation Support in Children With Hematologic Malignancies in Sweden

J Pediatr Hematol Oncol. 2021 Mar 1;43(2):e272-e275. doi: 10.1097/MPH.0000000000001808.

Abstract

Background: Extracorporeal membrane oxygenation (ECMO) is used in severe respiratory and/or circulatory failure when conventional critical care fails. Studies on patients with hematologic malignancies on ECMO have shown contradictory results; immunosuppression and coagulopathy are relative contraindications to ECMO.

Observations: This nationwide Swedish retrospective chart review identified 958 children with hematologic malignancies of whom 12 (1.3%) required ECMO support. Eight patients survived ECMO, 7 the total intensive care period, and 6 survived the underlying malignancy.

Conclusions: ECMO may be considered in children with hematologic malignancy. Short-term and long-term survival, in this limited group, was similar to that of children on ECMO at large.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Extracorporeal Membrane Oxygenation / mortality*
  • Female
  • Follow-Up Studies
  • Hematologic Neoplasms / mortality*
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / therapy
  • Humans
  • Infant
  • Male
  • Prognosis
  • Respiratory Insufficiency / mortality*
  • Respiratory Insufficiency / pathology
  • Respiratory Insufficiency / therapy
  • Retrospective Studies
  • Severity of Illness Index
  • Survival Rate
  • Sweden